雾化吸入重组人干扰素α2b治疗儿童社区获得性肺炎有效性与安全性的研究

Study on the effectiveness and safety of nebulized inhalation of recombinant human interferon α2b in the treatment of children with community-acquired pneumonia

目的研究雾化吸入重组人干扰素α2b治疗儿童社区获得性肺炎的有效性与安全性。方法选取桂平市人民医院2019年3月-2020年5月期间收治的160例社区获得性肺炎患儿为研究对象,按数字随机分组方法分为对照组(n=80)与试验组(n=80),对照组予以常规治疗,试验组在对照组基础上加用重组人干扰素α2b雾化吸入治疗,对2组患儿临床症状改善时间、治疗效果、住院时间、住院费用、治疗前后血白细胞(WBC)、C反应蛋白(CRP)与降钙素原(PCT)水平、肝肾功能及不良反应发生情况进行评价和比较。结果试验组临床症状缓解时间、三凹征、肺部啰音消失时间、住院时间及住院费用、治疗后症状评分总分与体征评分总分均比对照组低(P<0.05);试验组治疗总有效率比对照组高(P<0.05)。2组患儿治疗前后WBC及治疗前CRP、PCT无明显差异(P>0.05);试验组治疗后CRP、PCT低于对照组(P<0.05)。治疗前后2组患儿ALT、AST、BUN、Cr水平及治疗期间不良反应对比无明显差异(P>0.05)。结论对于儿童社区获得性肺炎给予重组人干扰素α2b雾化吸入治疗可以改善临床症状,缩短住院时间、降低住院费用,具有较高的安全性,值得临床应用。

Objective To study the effectiveness and safety of nebulized inhaled recombinant human interferonα2b in the treatment of children with community-acquired pneumonia.Methods 160 children with community-acquired pneumonia admitted in our hospital from March 2019 to May 2020 were selected as the research object,and were divided into a control group(n=80)and an experimental group(n=80),the control group is given routine treatment,the experimental group is added with recombinant human interferonα2b atomization inhalation treatment on the basis of the control group,and the clinical symptom improvement time,treatment effect,hospitalization time,hospitalization cost,liver before and after treatment are treated Evaluation and comparison of renal function and occurrence of adverse reactions.Results The clinical symptom relief time,three-concave sign,lung rales elimination time,hospitalization time and hospitalization cost in the experimental group were lower than those in the control group after treatment(P<0.05);The effective rate is higher than the control group(P<0.05);there is no significant difference in WBC and CRP and PCT before and after treatment between the two groups of patients(P>0.05)CRP and PCT after treatment are lower than the control group(P<0.05);There were no significant differences in the levels of ALT,AST,BUN,Cr and adverse reactions during treatment between the two groups(R>0.05).Conclusion For children with community-acquired pneumonia,the administration of recombinant human interferonα2b inhalation therapy can improve the clinical symptoms of children,shorten the length of hospital stay and reduce the cost of hospitalization.